



**CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

**中國神威藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*(在開曼群島註冊成立之有限公司)*

Website 網址：www.shineway.com.hk

**(Stock Code 股份代號：2877)**

**NOTIFICATION LETTER 通知信函**

20 September 2024

Dear registered shareholder(s),

**China Shineway Pharmaceutical Group Limited (the “Company”)  
– Notification of Publication of 2024 Interim Report (“2024 Interim Report”)**

We hereby notify you that the English and Chinese versions of the Company’s 2024 Interim Report are now available on the Company’s website at www.shineway.com.hk and on the HKEXnews website at www.hkexnews.hk.

If you want to receive the 2024 Interim Report and future Corporate Communications in printed form, please complete the Reply Form enclosed with the Notification on Arrangement of Electronic Dissemination of Corporate Communication issued by the Company on 11 March 2024 and send it to the Company’s Hong Kong share registrar (the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, or send an email to ChinaShineway.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form, or contact Customer Service Hotline of Share Registrar at (852) 2862 8555 from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Monday to Friday (excluding public holidays) and request to receive the Corporate Communications in printed form.

Yours faithfully,  
For and on behalf of  
**China Shineway Pharmaceutical Group Limited**  
**Lee Bun Ching Terence**  
Company Secretary

*Note:* Corporate Communications mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位登記股東：

**中國神威藥業集團有限公司(「本公司」)  
– 2024年中期報告(「2024年中期報告」)之發佈通知**

本公司謹此通知閣下2024年中期報告的英文及中文版本已登載於本公司網站(www.shineway.com.hk)及香港交易所披露易網站(www.hkexnews.hk)。

若閣下希望日後收取2024年中期報告及未來公司通訊的印刷版，請填寫本公司於2024年3月11日發出的《以電子方式發布公司通訊之安排》之回條，並寄至本公司香港辦事處股份過戶登記處(「股份過戶處」)香港中央證券登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓，或發送至電子郵件ChinaShineway.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求，或於週一至週五(公眾假期除外)上午9時正至下午6時正致電股份過戶處客戶服務熱線(852) 2862 8555並提出要求接收印刷版的公司通訊。

代表  
中國神威藥業集團有限公司  
李品正  
公司秘書  
謹啟

2024年9月20日

附註：公司通訊指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a)董事會報告、年度帳目連同核數師報告以及(如適用)財務摘要報告；(b)中期報告及(如適用)中期摘要報告；(c)會議通告；(d)上市文件；(e)通函；和(f)委任代表書。